{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:02:10Z","timestamp":1740117730057,"version":"3.37.3"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81101327"],"award-info":[{"award-number":["81101327"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.leukres.2019.01.012","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T02:06:50Z","timestamp":1548382010000},"page":"6-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway"],"prefix":"10.1016","volume":"79","author":[{"given":"Ye","family":"Yuanxin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Yanhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tang","family":"Sishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Minjin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Juan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Xiaojun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0601-1275","authenticated-orcid":false,"given":"Wang","family":"Lanlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Binwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2019.01.012_bib0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3324\/haematol.11891","article-title":"Karyotype at diagnosis is the major prognostic factor predicting relapse -free survival for patients with Philadelphia chromosome- positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy","volume":"93","author":"Yanada","year":"2008","journal-title":"Haematological"},{"key":"10.1016\/j.leukres.2019.01.012_bib0010","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2009-07-232124","article-title":"A population-based cytogenetic study of adults with acute lymphoblastic leukemia","volume":"115","author":"Moorman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.01.012_bib0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/asheducation-2011.1.361","article-title":"Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia","author":"Hunger","year":"2011","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.leukres.2019.01.012_bib0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Baccarani m; european LeukemiaNet. Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2019.01.012_bib0025","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.01.012_bib0030","doi-asserted-by":"crossref","first-page":"9961","DOI":"10.7314\/APJCP.2014.15.22.9961","article-title":"Clinical signifiance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias","volume":"15","author":"Ye","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.leukres.2019.01.012_bib0035","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.clml.2015.02.012","article-title":"Investigating the role of JAK\/STAT pathway on dasatinib-induced apoptosis for CML cell model K562","volume":"15","author":"Dalgic","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2019.01.012_bib0040","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2013.351","article-title":"PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis","volume":"28","author":"Berger","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.01.012_bib0045","doi-asserted-by":"crossref","first-page":"16596","DOI":"10.1074\/jbc.M111.319756","article-title":"Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine induced phospho- regulatory site that is constitutively activated in primary hematopoietic malignancies","volume":"287","author":"Mitra","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2019.01.012_bib0050","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.celrep.2014.10.039","article-title":"Kobayashi M.et.al. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis","volume":"9","author":"Chatterjee","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.leukres.2019.01.012_bib0055","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2009-12-258913","article-title":"Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation","volume":"116","author":"Friedbichler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.01.012_bib0060","first-page":"42","article-title":"Epigenetic modifications in pediatric acute lymPhoblastic leukemia","volume":"14","author":"Burke","year":"2014","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.leukres.2019.01.012_bib0065","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3324\/haematol.2014.116954","article-title":"Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"100","author":"Brissot","year":"2015","journal-title":"Haematologica"},{"issue":"653","key":"10.1016\/j.leukres.2019.01.012_bib0070","first-page":"661","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome- positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2019.01.012_bib0075","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/leu.2009.18","article-title":"Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions","volume":"23","author":"Mullighan","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.01.012_bib0080","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2017.36","article-title":"Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics","volume":"31","author":"Recke","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.01.012_bib0085","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1892","article-title":"p21-activated kinases in cancer","volume":"6","author":"Kumar","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2019.01.012_bib0090","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1038\/sj.onc.1209309","article-title":"PAK1 hyperactivation is sufficient for mammary gland tumor formation","volume":"25","author":"Wang","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2019.01.012_bib0095","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.01.012_bib0100","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00018-013-1519-6","article-title":"Small Rho GTPases in the control of cell shape and mobility","volume":"71","author":"Murali","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.leukres.2019.01.012_bib0105","doi-asserted-by":"crossref","first-page":"5826","DOI":"10.1038\/sj.onc.1204549","article-title":"Cooperative and redundant effects of STAT5 and Ras signaling in BCR-ABLtransformed hematopoietic cells","volume":"20","author":"Hoover","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2019.01.012_bib0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/1078-0432.CCR-14-0827","article-title":"Molecular pathways: targeting the kinase effectors of RHO-family GTPases","volume":"21","author":"Prudnikova","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2019.01.012_bib0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11010-009-0327-7","article-title":"A new Rac\/PAK\/GC\/cGMP signaling pathway","volume":"334","author":"Guo","year":"2010","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.leukres.2019.01.012_bib0120","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.exphem.2008.11.003","article-title":"Expression of P190 and P210 BCR\/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage","volume":"37","author":"J\u00e4r\u00e5s","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2019.01.012_bib0125","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/107327480901600202","article-title":"Signaling networks associated with BCR-ABL dependent transformation","volume":"16","author":"Hazlehurst","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.leukres.2019.01.012_bib0130","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1091\/mbc.e02-10-0653","article-title":"p38 Mitogen activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest","volume":"14","author":"Deacon","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.leukres.2019.01.012_bib0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1128\/MCB.20.2.453-461.2000","article-title":"p21-activated kinase 1 phosphorylates the death agonist Bad and protects cells from apoptosis","volume":"20","author":"Schurmann","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.leukres.2019.01.012_bib0140","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1158\/0008-5472.CAN-08-2103","article-title":"MiR-7, a Homeobox D10 Target, Inhibitsp21-Activated Kinase 1 and Regulates Its Functions","volume":"68","author":"Reddy","year":"2008","journal-title":"Cancer Res."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T02:45:23Z","timestamp":1573785923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619300189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":28,"alternative-id":["S0145212619300189"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.01.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}